Osi Pharms patents expiration
1. Tarceva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41065 | OSI PHARMS | Alkynl and azido-substituted 4-anilinoquinazolines |
Nov, 2018
(5 years ago) | |
| US5747498 | OSI PHARMS | Alkynyl and azido-substituted 4-anilinoquinazolines |
Nov, 2018
(5 years ago) | |
|
US5747498 (Pediatric) | OSI PHARMS | Alkynyl and azido-substituted 4-anilinoquinazolines |
May, 2019
(4 years ago) | |
|
USRE41065 (Pediatric) | OSI PHARMS | Alkynl and azido-substituted 4-anilinoquinazolines |
May, 2019
(4 years ago) | |
| US7087613 | OSI PHARMS | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
Nov, 2020
(3 years ago) | |
| US6900221 | OSI PHARMS | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
Nov, 2020
(3 years ago) | |
|
US7087613 (Pediatric) | OSI PHARMS | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
May, 2021
(2 years ago) | |
|
US6900221 (Pediatric) | OSI PHARMS | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
May, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-79) | Sep 19, 2011 |
| M(M-181) | Jun 01, 2019 |
| M(M-190) | Oct 18, 2019 |
| New Dosing Schedule(D-164) | May 20, 2019 |
| Pediatric Exclusivity(PED) | Nov 14, 2016 |
| New Indication(I-671) | May 14, 2016 |
| New Indication(I-624) | Apr 16, 2013 |
Drugs and Companies using ERLOTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 18 November, 2004
Treatment: Treatment of locally advanced or metastatic non small-cell lung cancer (nsclc) after failure of at least one prior chemotherapy regimen; Maintenance treatment in patients with locally advanced or meta...
Dosage: TABLET;ORAL
How can I launch a generic of TARCEVA before it's drug patent expiration?
More Information on Dosage
TARCEVA family patents
